British Journal of Psychiatry Publishes Results from Phase 3 Study of Alexza's AZ-004 for the Treatment of Agitation in Patients with Schizophrenia - Drugs.com MedNews
Links shared publicly online about this topic.
- 557total visits
British Journal of Psychiatry Publishes Results from Phase 3 Study of Alexza's AZ-004 for the Treatment of Agitation in Patients with Schizophrenia - Drugs.com MedNews
AZ-004 demonstrated statistically significant reductions in agitation compared with placebo as assessed by primary and key secondary endpoints AZ-004 was safe a
View full resource at drugs.com
Tags: Schizophrenia, Psychotic Disorder, Drug, Phase 3 Clinical Trial, Psychiatry, Psychology, Safety
Most Recently Shared on January 24, 2011 at 4:05 pm By:
British Journal of Psychiatry Publishes Results from Phase 3 Study of Alexza's AZ-004 for the Treatment of... http://bit.ly/gETDGV #drug
Advertisement
